Table 5 Therapeutic measures taken for patients with active psoriasis during a 12-Month follow-up
Medications | Previous (N = 78) | Baseline (N = 78) | 3 months (N = 55) | 6 months (N = 48) | 12 months (N = 40) | p |
|---|---|---|---|---|---|---|
No medication, n (%) | 23 (29.5%) | 0 | 0 | 0 | 0 | Â |
Topic Glucocorticoid, n (%) | 13 (16.7%) | 8 (10.3%) | 6 (10.9%) | 8 (16.7%) | 4 (10%) | 0.07 |
Oral systemic Glucocorticoids, n (%) | 6 (7.7%) | 3 (3.8%) | 1 (1.9%) | 1 (2.1%) | 1 (2.5%) | 0.26 |
DMARDs, n (%) | 43 (55.1%) | 68 (87.2%) | 28 (50.9%) | 21 (43.8%) | 12 (30%) |  < 0.0001 |
MTX, n (%) | 27 (34.6%) | 25 (32.1%) | 9 (16.4%) | 8 (16.7%) | 5 (12.5%) |  < 0.0001 |
LEF, n (%) | 9 (11.5%) | 3 (3.8%) | 5 (9.1%) | 6 (12.5%) | 2 (5.0%) | 0.001 |
SSZ, n (%) | 1 (1.3%) | 5 (6.4%) | 0 | 0 | 0 | 0.07 |
CsA, n (%) | 3 (3.8%) | 4 (5.1%) | 7 (12.7%) | 5 (10.4%) | 3 (7.5%) | 0.71 |
MTX + CsA, n (%) | 1 (1.3%) | 5 (6.4%) | 0 | 2 (4.2%) | 0 | 0.24 |
MTX + LEF, n (%) | 1 (1.3%) | 7 (9.0%) | 5 (9.1%) | 0 | 2 (5.0%) | 0.009 |
LEF + CsA, n (%) | 1 (1.3%) | 42 (53.8%) | 2 (3.6%) | 0 | 0 | 0.002 |
Biological agents, n (%) | 11 (14.1%) | 37 (47.4%) | 18 (32.7%) | 24 (50%) | 12 (30%) |  < 0.0001 |
TNF inhibitors, n (%) | 10 (12.8%) | 17 (21.8%) | 17 (30.9%) | 16 (33.3%) | 9 (22.5%) |  < 0.0001 |
Adalimumab, n (%) | 6 (7.7%) | 1 (1.3%) | 9 (16.4%) | 9 (18.8%) | 2 (5.0%) | 0.08 |
Golimumab, n (%) | 1 (1.3%) | Â | 0 | 2 (4.17%) | 2 (5.0%) | 0.64 |
Etanercept, n (%) | 0 | 13 (16.7%) | 7 (12.7%) | 2 (4.17%) | 3 (7.5%) |  < 0.0001 |
Infliximab, n (%) | 3 (3.8%) | 8 (10.3%) | 1 (1.9%) | 5 (10.4%) | 0 | 0.07 |
Abatacept, n (%) | 0 | 1 (1.3%) | 0 | 1 (2.8%) | 0 | 0.56 |
Ustekinumab, n (%) | 1 (1.3%) | 2 (2.6%) | 1 (1.9%) | 1 (2.8%) | 2 (5.0%) | 0.95 |
SECUKINUMAB, N (%) | 0 | 0 | 0 | 4 (8.3%) | 0 | 0.003 |